https://doi.org/10.4081/hmr.v2i5.382

Bortezomib in newly diagnosed multiple myeloma patients

Vol. 2 No. 5: Bortezomib (Velcade®) in multiple myeloma: an update
Published: June 8, 2009
Abstract Views: 169
PDF: 297
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Silvia Mangiacavalli
support@pagepress.org
High-dose therapy represents today the standard of care for younger multiple myeloma (MM) patients candidates to transplant. The induction phase is performed usually with VAD or VAD-like schemes which, however, produce a complete remission rate (CR) in less than 10%. Bortezomib (Velcade®) has demonstrated to be very effective in relapsed/refractory myeloma patients giving as single agent a CR rate of 16%, and several evidences indicate that bortezomib shows a synergistic activity with dexamethasone or other cytotoxic agents. Thus, taking into account that the achievement of a CR is the main objective in the treatment of MM, it is reasonable to introduce Bortezomib (Velcade®) as part of front-line high-dose programs. The application of bortezomib to novel front-line therapies depends in part on its effects on subsequent stem cell mobilization and engraftment.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Mangiacavalli, S. (2009). Bortezomib in newly diagnosed multiple myeloma patients. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.382
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).